Results 21 to 30 of about 7,425 (188)
Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment
Journal of Feline Medicine and Surgery Open Reports, 2021 Case summary A 7-year-old spayed female domestic shorthair cat weighing 5 kg was referred with polyuria, polydipsia, lethargy, abdominal distension and dermatologic abnormalities.
Diego D Miceli +4 more
doaj +1 more source
Cabergoline and the risk of valvular lesions in endocrine disease. [PDF]
, 2008 peer reviewedAIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.
Livadariu, E. +7 more
core +1 more source
A Practical Synthesis of Cabergoline [PDF]
The Journal of Organic Chemistry, 2002 Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders.
Scott W, Ashford +3 more
openaire +2 more sources
Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study [PDF]
, 2012 Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Utsumi, Hiroya +1 more
core +1 more source
Ожирение и метаболизм, 2015 Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed
Galina Afanas'evna Melnichenko +3 more
doaj +1 more source
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Indian Journal of Endocrinology and Metabolism, 2017 Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare +6 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2023 Background: There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on ...
Pouria Rahmanian-Devin +3 more
doaj +1 more source
Cabergoline Treatment in Invasive Giant Prolactinoma
, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Sadeem Alsubaie, Mussa H. Almalki
core +1 more source
Middle East Fertility Society Journal, 2011 Background: Prophylactic use of dopamine agonist has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). Objective: To compare cabergoline with cabergoline plus I.V albumin or I.V albumin alone in prevention of ...
Badeea S. Soliman
doaj +1 more source
De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline
Clinical Medicine Insights: Case Reports, 2023 Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de novo psychiatric symptoms during dopamine agonist therapy is low.
Chayma Belhadj Slimane +4 more
doaj +1 more source